Article Text

other Versions

Download PDFPDF
Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study
  1. Marisol Samartín-Ucha1,
  2. Jose Maria Pego-Reigosa1,
  3. Miriam Álvarez-Payero1,
  4. Alicia Martin-Vila1,
  5. Guadalupe Pineiro-Corrales1,
  6. Maria Rodriguez-Rodriguez1,
  7. Rafael Benito Melero-Gonzalez2,
  8. Francisco Maceiras-Pan2,
  9. Cristina Martinez-Reglero3,
  10. Noemi Mrtinez-Lopez de Castro1
  1. 1Pharmacy, University Hospital Complex of Vigo, VIGO, Spain
  2. 2Department of Rheumatology. University Hospital Complex of Vigo, Vigo, Spain
  3. 3Department of Methodology and Statistics, University Hospital Complex of Vigo, Vigo, Spain
  1. Correspondence to Marisol Samartín-Ucha, Pharmacy, University Hospital Complex of Vigo, Vigo 36212, Spain; marisol.samartin.ucha{at}


Objectives Medication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropathies: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Methods Single institution, descriptive, retrospective cohort study. Adult patients with chronic inflammatory arthropathies on BT between January 2009 and December 2016 were included. Persistence to BT was compared considering the type of pathology and treatment. The Kaplan–Meier test was used to analyse medication persistanence and factors associated with it. An analysis of reasons for therapy discontinuation was performed.

Results Three hundred and sixty-two patients were included in the study, which comprised 478 BT lines. For all patients, the 12-month persistence rate was 71.3% (341 out of 478). At the end of the study, 45.2% of the patients continued on their initial BT. Median treatment persistence was 1489 days (CI 95% 1195 to 1783). Longer BT persistence was associated with naïve BT patients: 1945 days (95% CI 1523 to 2367; P<0.001) and ankylosing spondylitis diagnosis: 2402 days (95% CI 1604 to 3200; P=0.014). The most frequent causes of treatment discontinuation were therapeutic failure (47.6%) and adverse drug events (28.2%).

Conclusions We found good long-term persistence in patients with chronic inflammatory arthropathies treated with BT. Patients with rheumatoid arthritis had significantly shorter persistence compared with those with ankylosing spondylitis and psoriatic arthritis. Naïve BT was associated with longer persistence. Therapeutic failure was the main cause of BT withdrawal.

  • clinical pharmacy
  • health economics
  • public health
  • rheumatology
  • side effects of drugs

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.